This study evaluates the effectiveness and safety of ulipristal acetae (UPA) in women with symptomatic uterine fibroids. Those who fulfilled inclusion/exclusion criteria will be treated UPA at daily dose of 5mg.
Who can participate
Age range18 Years – 48 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Women aged 18-48
* Regular cycle of 22-35 days interval and FSH \<=20 mUI/mL.
* \>=1 uterine fibroid of 3\<= d \< 10cm (regardless of location), diagnosed by transvaginal ultrasound.
* Heavy menstrual bleeding (blood loss \>80ml/cycle).
* Uterine size \< 16 weeks of GA on clinical examination.
* Agree to participate in the study.
Exclusion Criteria:
* Previous or current treatment of uterus, cervix, ovarian or breast cancer.
* Previous endometrial ablation or uterine artery embolization.
* Abnormal PAP's smear result within 12 months prior to recruitment.
* Endometrial hyperplasia within 6 months prior to recruitment.
* Uterine polyp \>2cm.
* Ovarian cysts 4cm diagnosed by transvaginal ultrasound.
* Severe anemia (Hb 6 g/dl) or indication for blood transfusion.
* Coagulation disorder indicated for treatment.
* Increased liver enzyme level of twofold or more than normal upper limit.
* Previous use of SPRM.
* Treatment of systemic progestin or intrauterine device or hormonal contraception within 2 months, or use of GnRH analogue within 5 months prior to recruitment.
* Current use of acetylsalicylic acid, mefenamic acid, anticoagulation agents, antifibrinolysis agents, or systemic corticoid
What they're measuring
1
Amenorrhea
Timeframe: from first dose to the end of 3 consecutive months of treatment course